

Koen De Geest, MD

Articles:

Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W; Gynecologic Oncology Group. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2009 Nov;115(2):215-20. Epub 2009 Aug 26.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. *J Clin Invest.* 2010 May 3;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. *J Clin Oncol.* 2010 Jun 1;28(16):2727-31. Epub 2010 Apr 26.

Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. *Gynecol Oncol.* 2010 Jun;117(3):440-5. Epub 2010 Mar 24.

Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK, Lubaroff DM, Lutgendorf SK. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. *Cancer.* 2010 Sep 15;116(18):4410-9.

Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers TE, Goodheart MJ, Antoni MH, Sood AK, Lubaroff DM. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. *Brain Behav Immun.* 2010 Nov;24(8):1231-40. Epub 2010 Jun 30.

Scholarly Publications

***Department of Obstetrics and Gynecology
University of Iowa, Iowa City, IA***

De Geest K

Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. *Gynecol Oncol.* 2010 Dec;119(3):484-90. Epub 2010 Sep 25.

Lutgendorf SK, Degeest K, Dahmouh L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. *Brain Behav Immun.* 2010 Oct 16. [Epub ahead of print]

Matei D, Sill MW, Lankes HA, Degeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial. *J Clin Oncol.* 2010 Nov 22. [Epub ahead of print]

Cella D, Huang H, Homesley HD, Montag A, Salani R, De Geest K, Lee R, Spirtos NM. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. *Gynecol Oncol.* 2010 Dec;119(3):538-42. Epub 2010 Sep 21.

Herzog TJ, Sill MW, Walker JL, O'Malley D, Shahin M, Degeest K, Weiner SA, Mutch D, Debernardo RL, Lentz SS. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q). *Gynecol Oncol.* 2010 Dec 16. [Epub ahead of print]

Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group. *Gynecol Oncol.* 2010 Dec 6. [Epub ahead of print]

Scholarly Publications

***Department of Obstetrics and Gynecology
University of Iowa, Iowa City, IA***

De Geest K